A highly potent ruthenium(II)-sonosensitizer and sonocatalyst for in vivo sonotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34408151.
- Also identified by DOI 10.1038/s41467-021-25303-1 and PMC identifier 8373944.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
As a basic structure of most polypyridinal metal complexes, [Ru(bpy)<sub>3</sub>]<sup>2+</sup>, has the advantages of simple structure, facile synthesis and high yield, which has great potential for scientific research and application. However, sonodynamic therapy (SDT) performance of [Ru(bpy)<sub>3</sub>]<sup>2+</sup> has not been investigated so far. SDT can overcome the tissue-penetration and phototoxicity problems compared to photodynamic therapy. Here, we report that [Ru(bpy)<sub>3</sub>]<sup>2+</sup> is a highly potent sonosensitizer and sonocatalyst for sonotherapy in vitro and in vivo. [Ru(bpy)<sub>3</sub>]<sup>2+</sup> can produce singlet oxygen (<sup>1</sup>O<sub>2</sub>) and sono-oxidize endogenous 1,4-dihydronicotinamide adenine dinucleotide (NADH) under ultrasound (US) stimulation in cancer cells. Furthermore, [Ru(bpy)<sub>3</sub>]<sup>2+</sup> enables effective destruction of mice tumors, and the therapeutic effect can reach deep tissues over 10 cm under US irradiation. This work paves a way for polypyridinal metal complexes to be applied to the noninvasive precise sonotherapy of cancer.
Medical subject headings
- Antineoplastic Agents
- Neoplasms
- Ruthenium
- Ultrasonic Therapy